SOL-804: Prostate cancer treatment

  • Bukwang’s formulation-focused subsidiary, Dyna Therapeutics (KR) has entered exclusive option agreement with Solural Pharm to license patented SOL-804 for WW right
     

  • SOL-804: new formulation of currently available drug with Lymphatic Targeting Technology
    Eliminates food effect
    Better safety profile due to reduced dosing level
     

  • Preclinical in 2017

|    ​Korean    |